Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Pfizer Global Research & Development
Femme et Homme Max 99 ans
Pfizer Global Research & Development
MAJ Il y a 4 ans
A 1-Year Open-Label Safety Extension Study of Pregabalin (CI-1008) in Patients With Anxiety Disorders
Main objective : • To evaluate under open-label conditions the long-term safety and tolerability of pregabalin in doses ranging from 150 to 600 mg/day.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Global Research & Development
MAJ Il y a 4 ans
A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-00915275 AFTER ORAL ADMINISTRATION TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS FOR 4-WEEKS
• To evaluate the effects of an oral dose of PF-00915275 (10 mg) on 24 hour mean daily glucose levels when administered as tablets for 4-weeks in subjects with T2DM.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Global Research & Development
MAJ Il y a 4 ans
A Placebo-Controlled Study of Pregabalin in Elderly Patients With Generalized Anxiety Disorder
1. To evaluate the efficacy of pregabalin versus placebo in relieving the symptoms of Generalized Anxiety Disorder as measured by Hamilton Anxiety Rating Scale (HAM-A) 2. Evaluate the safety of pregab...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations